Skip to main content
. 2023 Jul 6;14(9):1517–1535. doi: 10.1007/s13300-023-01438-w

Fig. 2.

Fig. 2

Proportion of patients who achieved the composite endpoint (A) or each endpoint (BF). The proportion of patients who achieved each endpoint was compared between the luseogliflozin and DPP-4i groups using the Chi-squared test. Asterisks indicate a significant difference between groups at *p < 0.05, **p < 0.01, and ***p < 0.001. eGFR Estimated glomerular filtration rate, HbA1c Hemoglobin A1c